153 related articles for article (PubMed ID: 11168039)
1. In vitro activity of macrolides against Bordetella pertussis strains isolated in 1968 and 30 years later in Poland.
Chodorowska M; Tyski S; Kuklińska D
Clin Microbiol Infect; 2000 Jan; 6(1):50-2. PubMed ID: 11168039
[No Abstract] [Full Text] [Related]
2. Effect of Macrolides and β-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough.
Mi YM; Hua CZ; Fang C; Liu JJ; Xie YP; Lin LN; Wang GL
Pediatr Infect Dis J; 2021 Feb; 40(2):87-90. PubMed ID: 33021592
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada.
Marchand-Austin A; Memari N; Patel SN; Tang P; Deeks SL; Jamieson FB; Crowcroft NS; Farrell DJ
Int J Antimicrob Agents; 2014 Jul; 44(1):82-4. PubMed ID: 24837412
[No Abstract] [Full Text] [Related]
4. Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance.
Fu P; Wang C; Tian H; Kang Z; Zeng M
Pediatr Infect Dis J; 2019 Apr; 38(4):370-376. PubMed ID: 30882726
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
6. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.
Hoppe JE
Infection; 1998; 26(4):242-6. PubMed ID: 9717684
[No Abstract] [Full Text] [Related]
7. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis.
Lewis K; Saubolle MA; Tenover FC; Rudinsky MF; Barbour SD; Cherry JD
Pediatr Infect Dis J; 1995 May; 14(5):388-91. PubMed ID: 7638015
[No Abstract] [Full Text] [Related]
8. Progressive respiratory distress in an infant treated for presumed pertussis.
Lee B
Pediatr Infect Dis J; 2000 May; 19(5):475, 492-3. PubMed ID: 10819348
[No Abstract] [Full Text] [Related]
9. In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen.
Hardy DJ; Vicino D; Fernandes P
Antimicrob Agents Chemother; 2016 Dec; 60(12):7043-7045. PubMed ID: 27620481
[TBL] [Abstract][Full Text] [Related]
10. Challenges and prospects in treating macrolide-resistant Bordetella pertussis in Chinese paediatric practice.
Yang R; Xu H; Zhang Z; Liu Q; Wu X
J Infect; 2024 Jul; 89(1):106185. PubMed ID: 38763390
[No Abstract] [Full Text] [Related]
11. Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington.
Galanakis E; Englund JA; Abe P; Qin X
Int J Antimicrob Agents; 2007 May; 29(5):609-11. PubMed ID: 17344029
[No Abstract] [Full Text] [Related]
12. Where macrolide resistance is prevalent.
Li Y; Liu X; Zhang B; He Q; Wang Z
APMIS; 2015 Apr; 123(4):361-3. PubMed ID: 25703275
[No Abstract] [Full Text] [Related]
13. Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.
Lönnqvist E; Barkoff AM; Mertsola J; He Q
J Glob Antimicrob Resist; 2018 Sep; 14():12-16. PubMed ID: 29486357
[TBL] [Abstract][Full Text] [Related]
14. The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
Yamaguchi T; Kawasaki Y; Katsukawa C; Kawahara R; Kawatsu K
Jpn J Infect Dis; 2020 Sep; 73(5):361-362. PubMed ID: 32350216
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Susceptibility and Molecular Detection of Pertactin-producing and Pertactin-Deficient Bordetella pertussis.
Souder E; Vodzak J; Evangelista AT; Long SS
Pediatr Infect Dis J; 2017 Jan; 36(1):119-121. PubMed ID: 27956730
[TBL] [Abstract][Full Text] [Related]
16. [Restriction analysis of Bordetella pertussis DNA isolated from patients with whooping cough in 1968 and 1995-98 and B. pertussis used for production of national vaccine strains].
Chodorowska M; Kuklińska D
Med Dosw Mikrobiol; 2000; 52(2):111-7. PubMed ID: 11107785
[TBL] [Abstract][Full Text] [Related]
17. Pertussis epidemiology in Tunisian infants and children and characterization of Bordetella pertussis isolates: results of a 9-year surveillance study, 2007 to 2016.
Ben Fraj I; Kechrid A; Guillot S; Bouchez V; Brisse S; Guiso N; Smaoui H
J Med Microbiol; 2019 Feb; 68(2):241-247. PubMed ID: 30526740
[TBL] [Abstract][Full Text] [Related]
18. Staying ahead of pertussis.
Rivard G; Viera A
J Fam Pract; 2014 Nov; 63(11):658-69. PubMed ID: 25362496
[TBL] [Abstract][Full Text] [Related]
19. Azithromycin for the treatment of pertussis.
Pichichero ME; Hoeger WJ; Casey JR
Pediatr Infect Dis J; 2003 Sep; 22(9):847-9. PubMed ID: 14515842
[No Abstract] [Full Text] [Related]
20. Severe pertussis infection in infants less than 6 months of age: Clinical manifestations and molecular characterization.
Stefanelli P; Buttinelli G; Vacca P; Tozzi AE; Midulla F; Carsetti R; Fedele G; Villani A; Concato C;
Hum Vaccin Immunother; 2017 May; 13(5):1073-1077. PubMed ID: 28129036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
